Loading…
Reported covered position: Deputy Chief of Staff, Rep. Mark Souder (IN-03)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FABIANI & COMPANY ON BEHALF OF OCTANE via MARTIN GREEN
2010 · fourth_quarter · 4T
Funding for innovation accelerator programs and conferences.
Funding for innovation accelerator programs and conferences.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), SENATE, Small Business Administration (SBA)
Source: Senate LDA
| FABIANI & COMPANY ON BEHALF OF CONCERT PHARMACEUTICALS | 4 | 2010 |
| FABIANI & COMPANY ON BEHALF OF OCTANE | 4 | 2010 |
| FABIANI & COMPANY ON BEHALF OF VARIATION BIOTECHNOLOGIES | 4 | 2010 |
| FABIANI & COMPANY ON BEHALF OF OCERA THERAPEUTICS INC. | 3 | 2009 |
| FABIANI & COMPANY ON BEHALF OF PLANET BIOTECHNOLOGY INC. | 3 | 2009 |
| FABIANI & COMPANY ON BEHALF OF TRF COALITION | 3 | 2009 |
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
FDA Food Safety Modernization Act
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
Patent reform legislation, including S. 510
FDA Food Safety Modernization Act
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
Patent reform legislation, including S. 510
FDA Food Safety Modernization Act
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
Patent reform legislation, including S. 510
FDA Food Safety Modernization Act
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
Patent reform legislation, including S. 510
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
S. 515, the Patent Reform Act
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
S. 515, the Patent Reform Act
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
American Middle Class Tax (AMT) Relief Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
American Middle Class Tax (AMT) Relief Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
H.R. 3590, the Patient Protection and Affordable Care Act -- therapeutic tax credit provision
American Middle Class Tax (AMT) Relief Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS · Firm: MARTIN GREEN
H.R. 3590, the Patient Protection and Affordable Care Act -- therapeutic tax credit provision
American Middle Class Tax (AMT) Relief Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
American Middle Class Tax (AMT) Relief Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
American Middle Class Tax (AMT) Relief Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Superfund Polluter Pays Act
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Superfund Polluter Pays Act
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Patent Reform Act of 2009
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
American Middle Class Tax (AMT) Relief Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Superfund Polluter Pays Act
Client: FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. · Firm: MARTIN GREEN
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Genomics and Personalized Medicine Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. · Firm: MARTIN GREEN
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Genomics and Personalized Medicine Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. · Firm: MARTIN GREEN
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Genomics and Personalized Medicine Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. · Firm: MARTIN GREEN
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Genomics and Personalized Medicine Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. · Firm: MARTIN GREEN
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Genomics and Personalized Medicine Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. · Firm: MARTIN GREEN
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Genomics and Personalized Medicine Act of 2007
Client: FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. · Firm: MARTIN GREEN
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. via MARTIN GREEN
2010 · fourth_quarter · 4T
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF MEDICAGO INC. via MARTIN GREEN
2010 · fourth_quarter · 4T
Funding to advance technology to support public health preparedness applications.
Funding to advance technology to support public health preparedness applications.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2010 · fourth_quarter · 4T
The Genomics and Personalized Medicine Act; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations; TRICARE reimbursement
The Genomics and Personalized Medicine Act of 2007; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Funding for pharmaceutical product research and development.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2010 · fourth_quarter · 4T
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS via MARTIN GREEN
2010 · fourth_quarter · 4T
Patent reform legislation, including S. 510
Patenting of genetic sequences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
FABIANI & COMPANY ON BEHALF OF OCTANE via MARTIN GREEN
2010 · third_quarter · Q3
Funding for innovation accelerator programs and conferences.
Funding for innovation accelerator programs and conferences.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), SENATE, Small Business Administration (SBA)
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2010 · third_quarter · Q3
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
FABIANI & COMPANY ON BEHALF OF VARIATION BIOTECHNOLOGIES via MARTIN GREEN
2010 · third_quarter · 3T
Funding for vaccine research and development
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. via MARTIN GREEN
2010 · third_quarter · Q3
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF MEDICAGO INC. via MARTIN GREEN
2010 · third_quarter · Q3
Funding to advance technology to support public health preparedness applications.
Funding to advance technology to support public health preparedness applications.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FABIANI & COMPANY ON BEHALF OF CONCERT PHARMACEUTICALS via MARTIN GREEN
2010 · third_quarter · 3T
Funding for drug and platform development
Funding for drug and platform development
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2010 · third_quarter · Q3
The Genomics and Personalized Medicine Act of 2007; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
The Genomics and Personalized Medicine Act; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations; TRICARE reimbursement
Funding for pharmaceutical product research and development.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS via MARTIN GREEN
2010 · third_quarter · Q3
Patenting of genetic sequences
Patent reform legislation, including S. 510
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. via MARTIN GREEN
2010 · second_quarter · Q2
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF VARIATION BIOTECHNOLOGIES via MARTIN GREEN
2010 · second_quarter · Q2
Funding for vaccine research and development
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF MEDICAGO INC. via MARTIN GREEN
2010 · second_quarter · Q2
Funding to advance technology to support public health preparedness applications.
Funding to advance technology to support public health preparedness applications.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FABIANI & COMPANY ON BEHALF OF CONCERT PHARMACEUTICALS via MARTIN GREEN
2010 · second_quarter · Q2
Funding for drug and platform development
Funding for drug and platform development
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2010 · second_quarter · Q2
The Genomics and Personalized Medicine Act of 2007; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Funding for pharmaceutical product research and development.
The Genomics and Personalized Medicine Act; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2010 · second_quarter · Q2
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS via MARTIN GREEN
2010 · second_quarter · Q2
Patent reform legislation, including S. 510
H.R. 3590, the Patient Protection and Affordable Care Act -- therapeutic tax credit provision
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF OCTANE via MARTIN GREEN
2010 · second_quarter · Q2
Funding for innovation accelerator programs and conferences.
Funding for innovation accelerator programs and conferences.
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), SENATE, Small Business Administration (SBA)
FABIANI & COMPANY ON BEHALF OF OCTANE via MARTIN GREEN
2010 · second_quarter · RR
Funding for innovation accelerator programs and conferences.
Funding for innovation accelerator programs and conferences.
FABIANI & COMPANY ON BEHALF OF VARIATION BIOTECHNOLOGIES via MARTIN GREEN
2010 · first_quarter · Q1
Funding for vaccine research and development
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF CONCERT PHARMACEUTICALS via MARTIN GREEN
2010 · first_quarter · Q1
Funding for drug and platform development
Funding for drug and platform development
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS via MARTIN GREEN
2010 · first_quarter · Q1
H.R. 3590, the Patient Protection and Affordable Care Act -- therapeutic tax credit provision
Patent reform legislation, including S. 510
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF VARIATION BIOTECHNOLOGIES via MARTIN GREEN
2010 · first_quarter · RR
Funding and parnerships with the Department of Defense and Department of Health and Human Services for vaccine research and development
Funding and parnerships with the Department of Defense and Department of Health and Human Services for vaccine research and development
Funding and parnerships with the Department of Defense and Department of Health and Human Services for vaccine research and development
FABIANI & COMPANY ON BEHALF OF CONCERT PHARMACEUTICALS via MARTIN GREEN
2010 · first_quarter · RR
Drug development for ocular infections, TBI/stroke related conditions, and HIV
Drug development for ocular infections, TBI/stroke related conditions, and HIV
FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. via MARTIN GREEN
2010 · first_quarter · Q1
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2010 · first_quarter · Q1
The Genomics and Personalized Medicine Act of 2007; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
The Genomics and Personalized Medicine Act; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Funding for pharmaceutical product research and development.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2010 · first_quarter · Q1
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
FABIANI & COMPANY ON BEHALF OF MEDICAGO INC. via MARTIN GREEN
2010 · first_quarter · Q1
Funding to advance technology to support public health preparedness applications.
Funding to advance technology to support public health preparedness applications.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FABIANI & COMPANY ON BEHALF OF ALNYLAM PHARMACEUTICALS via MARTIN GREEN
2010 · first_quarter · RR
S. 515, the Patent Reform Act
S. 515, the Patent Reform Act
FABIANI & COMPANY ON BEHALF OF LUNDBECK RESEARCH USA, INC. via MARTIN GREEN
2009 · fourth_quarter · 4T
Health Care Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF MEDICAGO INC. via MARTIN GREEN
2009 · fourth_quarter · RA
Funding to advance technology to support public health preparedness applications.
Funding to advance technology to support public health preparedness applications.
FABIANI & COMPANY ON BEHALF OF LUNDBECK RESEARCH USA, INC. via MARTIN GREEN
2009 · first_quarter · 1@
Health Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. via MARTIN GREEN
2009 · fourth_quarter · Q4
Provisions in health care reform legislation (including H.R. 3590, the Patient Protection and Affordable Care, and H.R.3962, the Affordable Health Care for America Act) pertaining to the medical device excise tax and Medicare reimbursements for medical imaging.
Provisions of the Patent Reform Act (S. 515 and H.R. 1260) relating to apportionment of damages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF MEDICAGO INC. via MARTIN GREEN
2009 · fourth_quarter · Q4
Funding to advance technology to support public health preparedness applications.
Funding to advance technology to support public health preparedness applications.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FABIANI & COMPANY ON BEHALF OF MEDICAGO INC. via MARTIN GREEN
2009 · fourth_quarter · RR
Funding to advance technology to support public health preparedness applications.
Funding to advance technology to support public health preparedness applications.
FABIANI & COMPANY ON BEHALF OF MEDRAD, INC. via MARTIN GREEN
2009 · fourth_quarter · RR
Health Care Reform and Patent Reform
Health Care Reform and Patent Reform
FABIANI & COMPANY ON BEHALF OF OCERA THERAPEUTICS, INC. via MARTIN GREEN
2009 · fourth_quarter · 4T
Funding for biopharmaceutical product development to address acute liver failure.
Funding for biopharmaceutical product development to address acute liver failure.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
FABIANI & COMPANY ON BEHALF OF LUNDBECK RESEARCH USA, INC. via MARTIN GREEN
2009 · fourth_quarter · Q4
Health Care Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2009 · fourth_quarter · Q4
The Genomics and Personalized Medicine Act of 2007; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
The Genomics and Personalized Medicine Act; Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2009 · fourth_quarter · Q4
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
FABIANI & COMPANY ON BEHALF OF OCERA THERAPEUTICS, INC. via MARTIN GREEN
2009 · third_quarter · Q3
Funding for biopharmaceutical product development to address acute liver failure.
Funding for biopharmaceutical product development to address acute liver failure.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
FABIANI & COMPANY ON BEHALF OF LUNDBECK RESEARCH USA, INC. via MARTIN GREEN
2009 · third_quarter · Q3
Health Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2009 · third_quarter · Q3
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2009 · third_quarter · Q3
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
FABIANI & COMPANY ON BEHALF OF OCERA THERAPEUTICS, INC. via MARTIN GREEN
2009 · third_quarter · RR
Funding for biopharmaceutical product development to address acute and chronic liver disease.
Funding for biopharmaceutical product development to address acute and chronic liver disease.
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2009 · second_quarter · Q2
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2009 · second_quarter · Q2
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF LUNDBECK RESEARCH USA, INC. via MARTIN GREEN
2009 · second_quarter · Q2
Health Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF PLANET BIOTECHNOLOGY, INC. via MARTIN GREEN
2009 · second_quarter · Q2
Department of Defense Appropriations Act, Fiscal Year 2010, provisions relating to Department of Defense medical research (RDT&E)
Department of Defense Appropriations Act, Fiscal Year 2010, provisions relating to Department of Defense medical research (RDT&E)
Department of Defense Appropriations Act, Fiscal Year 2010, funding for biodefense product research
FABIANI & COMPANY ON BEHALF OF TRF COALITION via MARTIN GREEN
2009 · second_quarter · 2T
Abuse-deterrent formulations of pharmaceutical products
Abuse-deterrent formulations of pharmaceutical products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF AUBURN UNIVERSITY via MARTIN GREEN
2009 · second_quarter · RR
Recognition of food safety center
Recognition of food safety center
Recognition of food safety center
FABIANI & COMPANY ON BEHALF OF TRF COALITION via MARTIN GREEN
2009 · first_quarter · Q1
Abuse-deterrent formulations of pharmaceutical products
Abuse-deterrent formulations of pharmaceutical products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF PLANET BIOTECHNOLOGY, INC. via MARTIN GREEN
2009 · first_quarter · Q1
Department of Defense Appropriations Act, Fiscal Year 2010, provisions relating to Department of Defense medical research (RDT&E)
Department of Defense Appropriations Act, Fiscal Year 2010, funding for biodefense product research
Department of Defense Appropriations Act, Fiscal Year 2010, provisions relating to Department of Defense medical research (RDT&E)
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FABIANI & COMPANY ON BEHALF OF LUNDBECK RESEARCH USA, INC. via MARTIN GREEN
2009 · first_quarter · Q1
Health Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2009 · first_quarter · Q1
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
S. 976, the Genomics and Personalized Medicine Act of 2007, Realizing the potential of personalized medicine; and Exclusive licensure of genetic associations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FABIANI & COMPANY ON BEHALF OF TRF COALITION via MARTIN GREEN
2009 · first_quarter · RR
Abuse-deterrent formulations of pharmaceutical products
Abuse-deterrent formulations of pharmaceutical products
FABIANI & COMPANY ON BEHALF OF CLINICAL DATA, INC. via MARTIN GREEN
2009 · first_quarter · RR
Realizing the potential of personalized medicine, and Exclusive licensure of genetic associations
Realizing the potential of personalized medicine, and Exclusive licensure of genetic associations
FABIANI & COMPANY ON BEHALF OF PLANET BIOTECHNOLOGY, INC. via MARTIN GREEN
2009 · first_quarter · RR
Funding for biodefense research
Funding for biodefense research
Funding for biodefense research
FABIANI & COMPANY ON BEHALF OF LUNDBECK RESEARCH USA, INC. via MARTIN GREEN
2009 · first_quarter · RR
Health Reform
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Funding and parnerships with the Department of Defense and Department of Health and Human Services for vaccine research and development
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Recognition of food saftey center
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Health sector training funding.
Filing targets: Defense, Dept of (DOD), Employment & Training Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Recognition of food safety center
Recognition of food safety center
Recognition of food safety center
Recognition of food safety center
Recognition of food safety center
Recognition of food safety center